Combination of chemotherapy, cancer cell vaccine and adoptive cell therapy
A combination of cancer cell vaccines, T cell activation, and chemotherapeutic agents addresses the limitations of current osteosarcoma treatments by enhancing the immune response and reducing toxicity, offering improved therapeutic outcomes.
Patent Information
- Application Number
- PCT/US2025/033332
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-06-14
- Filing Date
- 2025-06-12
- Publication Date
- 2025-12-18
AI Technical Summary
Current treatments for osteosarcoma in dogs, including surgery and adjuvant chemotherapy, offer only modest survival benefits and are rarely curative, with significant toxicity and handling challenges, while existing immunotherapies have not shown significant clinical benefit in diverse cancers.
A combination therapy involving a cancer cell vaccine with an immunologic adjuvant, T cell isolation and activation, and administration of activated T cells, optionally with chemotherapeutic agents before, during, or after these steps, to enhance the immune response against cancer cells.
This approach increases therapeutic efficacy with fewer chemotherapeutic doses, reducing side effects and promoting durable clinical effects by enhancing the immune response against cancer cells, potentially leading to more effective cancer treatment.
Smart Images
Figure US2025033332_18122025_PF_FP_ABST